Ocrelizumab extended‐interval dosing in multiple sclerosis during <scp>SARS‐CoV</scp>‐2 pandemic: a real‐world experience
Article 2023 en
Authors
SG
Simone Guerrieri
CB
Chiara Bucca
AN
Agostino Nozzolillo
Abstract
1 min read
Sporadic ocrelizumab administration delay granted sustained treatment efficacy in our cohort. Prospective data should be obtained to confirm these observations and set up systematic extended-interval regimens.
Frank Kloprogge, Lesley Workman, Steffen Borrmann, Mamadou Tékété, Gilbert Lefèvre, Kamal Hamed, Patrice Piola, Johan Ursing, Poul Erik Kofoed, Andreas Mårtensson, Billy Ngasala, Anders Björkman, Michael Ashton, Sofia Friberg Hietala, Francesca Aweeka, Sunil Parikh, Leah Mwai, Timothy M. E. Davis, Harin Karunajeewa, Sam Salman, Francesco Checchi, Carole Fogg, Paul N. Newton,
Discussion(0)
No comments yet. Be the first to comment.